



Product Information Sheet

Monoclonal Anti-p16^{INK4a/CDKN2}

Catalogue No. MA1074

Immunogen

Recombinant human p16 protein

Lot No. 08A12

Purification

Purified by the goat anti-mouse IgG affinity chromatography.

Clone: IMD-16

Ig type: mouse IgG2a

Application

Western blot

At 0.5-1µg/ml with the appropriate system to detect P16 in cells and tissues.

Size: 100µg/vial

Immunohistochemistry(F)

At 1-2µg/ml to detect P16 in formalin fixed and paraffin embedded tissues.

Specificity

Human.

No cross reactivity with other proteins.

Immunocytochemistry

Suitable

Other applications have not been tested.

Optimal dilutions should be determined by end user.

Recommended application

Western blot

Immunohistochemistry(F)

Immunocytochemistry

Formulation

Lyophilized from 1.2% sodium acetate, with 2mg BSA and 0.01mg NaN₃ as preservative.

Reconstitution

1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, the antibody concentration will be 100µg/ml.

To reorder contact us at:

Antagene, Inc.

Toll Free: 1(866)964-2589

email: Info@antageneinc.com

Storage

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for longer time.

BACKGROUND

p16(INK4A), also known as cyclin-dependent kinase inhibitor 2A(CDKN2A), or multiple tumor suppressor 1(MTS1). The p16 gene (CDKN2A) was mapped to 9p21. The p16 gene encodes a negative regulator of the cell cycle. CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas. Germ-line mutations in the CDKN2A tumor-suppressor gene have been linked to the development of melanoma in some families

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE.

with inherited melanoma.

REFERENCE

1. Stone, S.; Jiang, P.; Dayananth, P.; Tavtigian, S. W.; Katcher, H.; Parry, D.; Peters, G.; Kamb, A. : Complex structure and regulation of the p16(MTS1) locus. *Cancer Res.* 55: 2988-2994, 1995.
2. Monzon, J.; Liu, L.; Brill, H.; Goldstein, A. M.; Tucker, M. A.; From, L.; McLaughlin, J.; Hogg, D.; Lassam, N. J. : CDKN2A mutations in multiple primary melanomas. *New Eng. J. Med.* 338: 879-887, 1998.
3. Bartsch, D.; Shevlin, D. W.; Tung, W. S.; Kisker, O.; Wells, S. A., Jr.; Goodfellow, P. J. : Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. *Genes Chromosomes Cancer* 14: 189-195, 1995